Zobrazeno 1 - 10
of 19
pro vyhledávání: '"R H B, Meyboom"'
Autor:
Patrick C. Souverein, B.M. Verdel, S. H. Kardaun, Hubert G. M. Leufkens, R. H. B. Meyboom, Antoine C. G. Egberts
Publikováno v:
Pharmacoepidemiology and Drug Safety. 18:602-609
Background Drug-induced photosensitivity is difficult to predict and remains a challenge for both the dermatological clinical practice and pharmacovigilance. Purpose To assess the association between spectroscopic and molecular characteristics and th
Autor:
J. D. Vries, J. Zuidema, Trea A. Galiën, G. T. Werf, H. Wesseling, Herre Talsma, A. C. Eissens, Ilva Bommel, N. Stecher, C. M. Ree, M. Olling, B. Steffens, R. J. M. Hooff, K. S. Beuning, M. W. Lammers, W. I. Iwema Bakker, H. J. Haisma, D. A. Piers, A. N. Fransz, R. A. M. Kengen, P. Salomons, G. H. P. Wierik, Russell C. Coile, L. M. Bouter, Marco C. Stehouwer, J. Medema, J. G. W. Kosterink, W. N. E. Wolthuis, D. J. Touw, G. M. Visser, A. Dijk, D. R. A. Uges, Anke M. Trigtv, A. Knevelman, R. Stewart, H. Junginger, J. A. A. M. Kamps, H. E. Boddé, Jacobus Swart, J. R. Marler, Bruno H. Stricker, R. H. P. Smit, J. Biller, N. E. H. W. Hendrikx, Rein Vos, F. J. W. Mansvelt, S. S. N. Graaf, R. H. B. Meyboom, J. Hermans, W. Brand, E. J. F. Franssen, H. P. Adams, L. Leij, Hubert G. M. Leufkens, Ferd Sturmans, P. J. Reinhoud, I. H. Go, D. N. Reinhoudt, A. T. P. Skrabanja, J. W. F. Mil, M. M. W. B. Hendriks, H. S. Lau, T. Hultermans, A.J.M. Schoonen, R. Wolters, G. Storm, M. W. Versantvoort, L. J. Stokx, G. H. P. Koning, Albert Bakker, Anthonius Boer, J. Velden, B. A. Ruben, G. Luurtsema, W. E. Hennink, T. Beumer, A. H. P. Paes, H. G. M. Leufkens, C. Oussoren, R. J. Boskma, Peter W. Swaan, Nicolien Wieringa, de Dick Zeeuw, D. A. Bloemhof, B. Mevboom-de Jong, Ellis J. C. Boerkamp, K. J. C. Wientjes, G. Th. van der Werf, J. M. L. Engelen, E. R. Heerdink, J. E. Leysen, Anthonius de Boer, Inge H. Reuvers, D. de Boer, Yechiel A. Hekster, Auke Bult, Ron M. C. Herings, M. C. Cornel, C. Thomas, H. N. Magnani, P. M. L. A. Bemt, A. Schotte, H. A. Tissot van Patot, L. Veehof, E. C. A. Winden, Andrew Herxheimer, D. Shochat, D. Post, B. Struska, Harry Meinardi, P. H. Elsinga, H. Bloemhof, E. Postma-Lim, G. J. Driessen, R. M. E. Franssen, Donald R. A. Uges, J. H. Proost, Jennifer Heijman, J. Dijk, Arnold B. Bakker, L. M. L. Slolk, D. M. Barends, Henk Vos, J. C. Verhoef, Eric J. F. Franssen, Jenny Hettelaar, J. A. Leusink, Y. M. Groot-Padberg, M. J. Steenbergen, Margot Jeronimus-Stratingh, A. G. Rauws, H. G. A. Mokkink, L. E. Visser, L. Flendrig, W.H.M. Craane-van Hinsberg, H. R. M. Gorissen, M. Danhof, Eric J. C. Blok, P. Denig, L. T. W. Jong-van den Berg, P. F. M. Janssen, Hugo Paauw, F. J. Schmidt, H. Vromans, M. Foets, F. v. Dinther, T. F. J. Tromp, H. J. C. Wit, Cf Lerk, E. W. Massey, J. Fennis, E. W. M. Schrijnemakers, P. J. Swart, Miriam C. J. M. Sturkenboom, J. H. Beijnen, Jan I. Jmker, B. M. Jongh, W. Vaalburg, Eibert R. Heerdink, Flora M. Haaijer-Ruskamp, Daan J.A. Crommelin, M. Haas, F. W. J. Gribnau, B. J. Smit, J. J. H. Thijssen, M. Kuipers, Michiel H. De Vries, J. Raemaekers, C. E. M. Gelderen, F. W. Dijkers, A. M. Nijenhuis, Hubert G. Leufkens, Hans Kaldeway, Andries Bruins, D. K. F. Meijer, Miriam Mol, J. J. Tukker, Alma Middeibeek, John Urquhart, F. M. Haaijer-Ruskamp, Jan C. Reuyl, J. N. Davis, M. K. Casparie, M. H. Vingerhoeds, Floor Rikken, A. A. T. M. M. Vinks, A. Keyser, Jaap Willems, Lolkje T. W. de Jong-van den Berg, Albert Versluis, P. M. J. Stuvt, J. E. Nagtegaal, M. W. A. Jonge, J. M. K. H. Wierda, E. F. Smit, B. H. Ch. Stricker, Arijan J. Porsius, J. C. H. Borchert, J. W. Gubbels, S. W. F. Omta, G. L. Scherphof, H. Lier, K. Wiedhaup, D. K. F. Mijer, Max Maas, Jan W. Kijne, F. Iren, A. Kuijpers, J. Meulenbelt, H. G. M. Heijerman, Willy O. Renier, P. J. M. Kil, Jrbj Brouwers, E. T. J. Peters, Dick F. J. Tromp, Wim Vaalburg, Geb Visser, Lolkie T. W. Jong vd Berg, M. C. J. M. Sturkenboom, Gert Luurtsema, W. Bakker, C. Florax
Publikováno v:
Pharmacy World & Science. 15:K3-K22
Autor:
R. H. B. Meyboom, R. J. Royer
Publikováno v:
Pharmacoepidemiology & Drug Safety. 1:87-97
Publikováno v:
Pharmacoepidemiology and drug safety. 18(7)
Drug-induced photosensitivity is difficult to predict and remains a challenge for both the dermatological clinical practice and pharmacovigilance.To assess the association between spectroscopic and molecular characteristics and the occurrence of phot
Publikováno v:
Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti. 56(1)
Tumourous diseases are associated with haemorrhagic as well as thrombotic complications. Trousseau described in 1865 a mutual association between tumourous diseases and venous thromboembolism. As many as 15-20% patients with venous thromboembolism ha
Autor:
R. H. B. Meyboom
Publikováno v:
Pharmacoepidemiology and Drug Safety. 7:S63-S65
Publikováno v:
Pharmcoepidemiology and Drug Safety, 10(2), 135-142. Wiley
Purpose The antifungal agent terbinafine has been approved for marketing in The Netherlands since 1992. Adverse drug reactions (ADRs) may occur in about 10% of the patients, the majority gastrointestinal disorders and skin reactions. Since the introd
Autor:
R. H. B. Meyboom, Maartje Smulders, Toine C. G. Egberts, Hubert G. M. Leufkens, F. H. P. De Koning
The occurrence of previously unknown adverse reactions after the marketing of a new drug is inevitable given the limitations of preregistration clinical trials. Nevertheless, their impact on public health should be minimised by ensuring that reaction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4374d32120920adb69f447550735c561
https://europepmc.org/articles/PMC2351951/
https://europepmc.org/articles/PMC2351951/
The Triazolam Experience in 1979 in The Netherlands, a Problem of Signal Generation and Verification
Autor:
R. H. B. Meyboom
Publikováno v:
Drug Epidemiology and Post-Marketing Surveillance ISBN: 9781489925893
Triazolam (Halcion) was marketed as a hypnotic in the Netherlands early in 1978. There were tablets of three different strengths: 0.25, 0.5, and 1 mg. The product information recommended a dose of “0.25–0.5 mg for elderly patients who have not al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::907b4adb976292c1ab45f13460522c0f
https://doi.org/10.1007/978-1-4899-2587-9_19
https://doi.org/10.1007/978-1-4899-2587-9_19
Publikováno v:
Pharmacoepidemiology and Drug Safety. 8:S63-S64